Benefits
Body Weight, Waist, and BMI Reduction
An RCT in obese pre-menopausal women showed significant decreases in body weight, waist circumference, and BMI with yacon syrup at 0.14 g FOS/kg/day. The effect size was modest but clinically meaningful in this population.
Insulin Resistance Improvement
Trial data documented significant decreases in fasting serum insulin and HOMA-IR (Homeostasis Model Assessment for Insulin Resistance) in participants with baseline elevated HOMA-IR. No effect on fasting glucose (already normo-glycemic). Effects align with FOS-mediated GLP-1 elevation and gut microbiome modulation.
LDL Cholesterol Reduction
Trial data found a significant decrease in serum LDL-cholesterol with yacon syrup, while total cholesterol and triglycerides were not significantly changed. A systematic review confirmed LDL reduction as a consistent finding across yacon trials.
Increased Defecation Frequency and Satiety
Trial data documented increased defecation frequency and satiety sensation with yacon syrup. FOS is a well-established prebiotic and bulk-forming dietary fiber; satiety effects likely involve FOS-mediated GLP-1 and PYY elevation. Gut transit benefits are consistent across studies.
Prebiotic / Gut Microbiome Support
FOS is selectively fermented by Bifidobacterium and Lactobacillus species, supporting beneficial gut microbiome composition. This is the same mechanism as inulin and other fructan prebiotics. A systematic review noted improvements in intestinal transit and gut microbiota across yacon trials.
Mechanism of action
Fructooligosaccharide (FOS) Prebiotic Effect
Yacon syrup is exceptionally rich in inulin-type FOS (40-70% of dry weight) — among the highest natural sources known. FOS is non-digestible by human enzymes but selectively fermented by colonic Bifidobacterium and Lactobacillus, producing short-chain fatty acids (SCFAs: acetate, propionate, butyrate) with metabolic and anti-inflammatory benefits.
GLP-1 and PYY Elevation (Incretin/Satiety Hormones)
Colonic SCFA production from FOS fermentation stimulates L-cell secretion of GLP-1 (incretin, postprandial insulin enhancer) and PYY (peptide YY, satiety hormone). This explains the satiety and insulin sensitivity benefits documented in trials.
Reduced Caloric Density (Low-Glycemic Sweetener)
FOS provides ~1.5-2 kcal/g vs. ~4 kcal/g for sucrose — and most of those calories come from colonic SCFAs that are partially used by gut bacteria. As a sweetener replacement, yacon syrup substantially reduces glycemic load and net caloric impact.
Bulk Stool Formation and Transit
Like other soluble fibers, FOS adds water-binding bulk to stool and may accelerate colonic transit. This explains the increased defecation frequency seen in trials and supports general gut health applications.
Modest Mineral Absorption Enhancement
FOS may modestly enhance calcium and magnesium absorption via colonic SCFA-induced mineral solubilization. Effects are real but usually small; relevance for osteoporosis prevention is mechanism-based rather than RCT-confirmed for yacon specifically.
Clinical trials
Double-blind, placebo-controlled trial. Two doses of yacon syrup (0.29 g and 0.14 g FOS/kg/day) vs. placebo for 120 days in obese pre-menopausal women. Anthropometric measurements, blood glucose, calcium, lipid and insulin concentrations, HOMA-IR. (Genta, Cabrera, Habib, Pons, Carillo, Grau, Sánchez 2009, Clin Nutr)
Obese, slightly dyslipidemic pre-menopausal women with baseline insulin resistance (HOMA-IR > 2.70).
Recommended dose without GI side effects: 0.14 g FOS/kg/day. Significant decreases in body weight, waist circumference, and BMI. Significant decreases in fasting serum insulin and HOMA-IR. Significant LDL cholesterol reduction. Increased defecation frequency and satiety sensation. Fasting glucose unchanged. Higher dose (0.29 g/kg) caused GI side effects. Foundational clinical trial establishing yacon syrup as a beneficial functional food for obese insulin-resistant women.
PRISMA-compliant evidence review of yacon syrup clinical trials over the last decade. Searched Medline (PubMed), Science Direct, Embase, Scopus, SciELO through. Inclusion: clinical trials of yacon syrup on glycemic control, lipid profile, insulin sensitivity, appetite regulation, gut microbiota in healthy/overweight/obese individuals. (Nutrients)
7 clinical trials included, totaling 161 participants from diverse populations.
Yacon syrup supplementation demonstrated significant reductions in fasting insulin, HOMA-IR, and LDL cholesterol, alongside improvements in satiety and intestinal transit. Findings were consistent across trial heterogeneity. Authors noted evidence quality concerns (small sample sizes, dose variability) and called for larger trials.
Randomized, double-blind, placebo-controlled clinical trial of yacon flour vs. placebo in overweight adults. Outcomes: body composition, intestinal function. (Machado, da Silva, Chaves, Clin Nutr ESPEN)
Overweight adults.
Yacon flour consumption improved body composition and intestinal function vs. placebo. Provides additional evidence beyond syrup form that yacon-derived FOS supports weight management and gut function. Effect sizes modest but consistent with mechanism.